In three independent experiments, we tested whether SCD inhibition impedes tumor growth during the initial (lag) phase, exponential (log/progression) phase as a single agent (monotherapy), and during progression of advanced tumors in combination therapy with temozolomide (TMZ), the standard of care DNA alkylating agent for GBM. Here, SCD is linked to neoplasm.